公开(公告)号：US20230066088A1

公开(公告)日：2023-03-02

申请号：US17700027

申请日：2022-03-21

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Susan Ashwell ,  Blythe Thomson ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/00

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US11311527B2

公开(公告)日：2022-04-26

申请号：US16893147

申请日：2020-06-04

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Susan Ashwell ,  Blythe Thomson ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/00

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US11738018B2

公开(公告)日：2023-08-29

申请号：US17243177

申请日：2021-04-28

Applicant: FORMA Therapeutics, Inc.

Inventor： Susan Ashwell ,  Blythe Thomson ,  Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Wei Lu

IPC: A61K31/4709 ,  A61K31/706 ,  A61P35/02 ,  A61P35/00

CPC classification number: A61K31/4709 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US11497743B2

公开(公告)日：2022-11-15

申请号：US17112269

申请日：2020-12-04

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Susan Ashwell ,  Blythe Thomson ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/02 ,  C12Q1/686 ,  C12Q1/6886

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

公开(公告)号：US20250082628A1

公开(公告)日：2025-03-13

申请号：US18611335

申请日：2024-03-20

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Susan Ashwell ,  Blythe Thomson ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/00

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US20230101121A1

公开(公告)日：2023-03-30

申请号：US17986414

申请日：2022-11-14

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Susan Ashwell ,  Blythe Thomson ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/02 ,  C12Q1/686 ,  C12Q1/6886

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

公开(公告)号：US11576906B2

公开(公告)日：2023-02-14

申请号：US16414505

申请日：2019-05-16

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Susan Ashwell ,  Blythe Thomson ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/00 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K31/7068

Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

公开(公告)号：US11963956B2

公开(公告)日：2024-04-23

申请号：US17700027

申请日：2022-03-21

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Susan Ashwell ,  Blythe Thomson ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/00

CPC classification number: A61K31/4709 ,  A61P35/00

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US11013734B2

公开(公告)日：2021-05-25

申请号：US16526593

申请日：2019-07-30

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Susan Ashwell ,  Blythe Thomson ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/02 ,  C12Q1/686 ,  C12Q1/6886

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

公开(公告)号：US20190350922A1

公开(公告)日：2019-11-21

申请号：US16526593

申请日：2019-07-30

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker

IPC: A61K31/4709 ,  A61P35/02 ,  C12Q1/686 ,  C12Q1/6886

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.